Seragon Completes Pre-Clinical Study of Aging Intervention Candidate SRN-901

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Seragon-SRN-901

More Like This

Sirius Therapeutics Announces Promising Phase I Clinical Data from Its Factor XI siRNA, a Long-Acting Next-Generation Anticoagulant for Thromboembolic Disorders

Sirius Therapeutics to Present Data from Its Phase 1 Clinical Trial of Factor XI siRNA, a Long-Acting Next-Generation Anticoagulant for Thromboembolic Disorders at the 66th ASH Annual Meeting and Exposition

Extracellular Nanoparticles Sourced From Another Species Reverses Biological Age of Rats by More Than 50%

Sirius Therapeutics Begins Phase 1 Clinical Trial of Next-Generation, Long-Acting Factor XI siRNA Anticoagulant for Treatment of Thromboembolic Disorders

Sirius Therapeutics Announces Submission to Begin First Clinical Trial of Factor XI siRNA, a Long-Acting Next-Generation Anticoagulant for Thromboembolic Disorders

PR Newswire associated0

S&E bio Receives Korea's First Approval for Exosome-Based Therapy Clinical Trial

Rejuveron Life Sciences AG Rebrands as Centenara Labs AG and Provides Latest Clinical Updates

PR Newswire associated0

LifeSpan Vision Ventures Makes 7th Investment in Pursuit of Longevity Mission